The Optimizing Treatment of PegIFN Alfa in HBeAg-negative CHB Patients With Low Level HBsAg
The Optimizing Treatment of PegIFN Alfa in HBeAg-negative Chronic Hepatitis B Patients With Low Level HBsAg
Sponsor: First Affiliated Hospital of Kunming Medical University
Listed as NCT02745704, this PHASE4 trial focuses on Chronic Hepatitis B and remains ongoing. Sponsored by First Affiliated Hospital of Kunming Medical University, it has been updated 9 times since 2016, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE4
Status: Unknown Status → Unknown
-
Apr 2023 — Jul 2024 [monthly]
Unknown Status PHASE4
-
Feb 2021 — Apr 2023 [monthly]
Unknown Status PHASE4
Status: Recruiting → Unknown Status
-
Jan 2021 — Feb 2021 [monthly]
Recruiting PHASE4
▶ Show 4 earlier versions
-
Feb 2019 — Jan 2021 [monthly]
Recruiting PHASE4
-
Jun 2018 — Feb 2019 [monthly]
Recruiting PHASE4
-
Jun 2017 — Jun 2018 [monthly]
Recruiting PHASE4
-
Jan 2017 — Jun 2017 [monthly]
Recruiting PHASE4
First recorded
Apr 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- First Affiliated Hospital of Kunming Medical University
- First People's Hospital of Foshan
- First People's Hospital, Shunde China
- Huazhong University of Science and Technology
- Huizhou Municipal Central Hospital
- Nanchang University
- Peking University
- Shenzhen Third People's Hospital
- Tang-Du Hospital
- Third Affiliated Hospital, Sun Yat-Sen University
- Yuebei People's Hospital
For direct contact, visit the study record on ClinicalTrials.gov .